pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·1h ago·1 min read
save

Bexorg names Bruce Car as new chief scientific officer

Jul 31, 2026·read at STAT ↗Positive

Bexorg announced the appointment of Bruce Car as its chief scientific officer, according to a recent STAT+ column that tracks personnel moves in the pharmaceutical sector.

Car joins Bexorg to lead scientific strategy and research initiatives. The announcement was part of a regular feature highlighting new hires, promotions and transfers across the industry.

The hiring reflects Bexorg's effort to strengthen its leadership team amid ongoing competition for talent in drug development and related fields.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Up and down the ladder: The latest comings and goings”

read at STAT ↗
461 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
RISING2LILLYNOVO
topics
Duchenne Muscular Dystrophy2Melanoma

related stories

  • 3h agoSTAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and moreSTAT
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • 21h agoCapricor’s data clash and a fugitive in the C-suiteSTAT
  • 1d agoSTAT+: Rising oil prices can boost the cost of some medicines. One expert says it’s time to lower reliance on fossil fuelsSTAT
  • 2d agoGSK cost-cutting plan includes global layoffsBioSpace